As the U.S. market experiences a mixed performance, with the Dow Jones Industrial Average retreating from record highs and major indices showing varied results, investors are keenly observing economic indicators and corporate earnings reports. Amidst this backdrop of fluctuating market sentiment and potential interest rate cuts, small-cap stocks often present unique opportunities due to their growth potential and agility in adapting to changing conditions. In such an environment, identifying small-cap stocks that demonstrate strong fundamentals and insider buying can be a strategic move for investors looking to explore undervalued opportunities.
|
Name |
PE |
PS |
Discount to Fair Value |
Value Rating |
|---|---|---|---|---|
|
PCB Bancorp |
10.3x |
3.1x |
30.62% |
★★★★★☆ |
|
First United |
10.0x |
2.9x |
43.77% |
★★★★★☆ |
|
Tandem Diabetes Care |
NA |
0.8x |
49.98% |
★★★★★☆ |
|
Industrial Logistics Properties Trust |
NA |
0.9x |
20.32% |
★★★★★☆ |
|
Citizens & Northern |
11.7x |
2.9x |
41.08% |
★★★★☆☆ |
|
S&T Bancorp |
11.4x |
3.9x |
37.56% |
★★★★☆☆ |
|
Thryv Holdings |
NA |
0.8x |
25.55% |
★★★★☆☆ |
|
GEN Restaurant Group |
NA |
0.1x |
-612.57% |
★★★★☆☆ |
|
Shore Bancshares |
10.4x |
2.7x |
-83.77% |
★★★☆☆☆ |
|
Farmland Partners |
7.2x |
8.7x |
-44.53% |
★★★☆☆☆ |
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Value Rating: ★★★★★☆
Overview: Tandem Diabetes Care specializes in designing and manufacturing insulin pumps and related supplies, with a market capitalization of approximately $1.12 billion.
Operations: The company generates revenue primarily from insulin pumps and supplies, amounting to $1.00 billion. The cost of goods sold (COGS) for the same period is $475.35 million, resulting in a gross profit of $526.37 million with a gross profit margin of 52.55%. Operating expenses are significant at $619.40 million, including research and development costs of $199.36 million and general & administrative expenses totaling $420.04 million, contributing to a net income loss of -$205.45 million with a net income margin of -20.51%.
PE: -4.0x
Tandem Diabetes Care, a small company in the U.S., recently received FDA clearance for their SteadiSet infusion set, enhancing their product lineup. Despite a net loss of US$52.4 million in Q2 2025, sales increased to US$240.68 million from the previous year. The company's earnings are projected to grow by 75% annually. Insider confidence is evident with recent share purchases, suggesting belief in future prospects despite current challenges like a voluntary recall for t:slim X2 pumps due to speaker issues.
